• Explore /
  • Poster
  • / Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.

Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.

Abstract Poster

Authors

Xue-ning Yang

Xue-ning Yang

Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Xue-ning Yang , Wenzhao Zhong , Xiao-song Ben , Gui-bin Qiao , Qun Wang , Chang-li Wang , Hong-He Luo , Zheng Wang , Hong-Hong Yan , Si-yang Liu , Yi-Long Wu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00321334

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8508)

DOI

10.1200/JCO.2018.36.15_suppl.8508

Abstract #

8508

Poster Bd #

114

Abstract Disclosures

Similar Posters

First Author: Xue-Ning Yang

First Author: Tina Cascone

First Author: Winston Wong

First Author: Virginia Calvo